Use of UV mutational signatures to distinguish between cutaneous and pulmonary primary squamous cell carcinoma
When cases of PLO-SCC undergo CGP, a small 2.5% subset of cases that featured a UV MS emerge that indicates that these tumors may actually represent metastatic cutaneous SCC or BCC with squamous differentiation. Given the significant treatment and clinical impact associated with the resolution of the true diagnosis of these cases, the use of genomic sequencing in PLO-SCC may be clinically beneficial.
Authors
- Julie Y. Tse (ORCID: https://orcid.org/0000-0001-8648-5288)
- Stephen L. Graziano
- Dean Pavlick
- Alina Basnet (ORCID: https://orcid.org/0000-0002-6033-6943)
- Richard S.P. Huang (ORCID: https://orcid.org/0000-0001-8395-5168)
- Erik A. Williams (ORCID: https://orcid.org/0000-0002-9190-2450)
- Rami N. Al‐Rohil (ORCID: https://orcid.org/0000-0002-9431-0530)
- Ethan S. Sokol (ORCID: https://orcid.org/0000-0002-2988-0537)
- Jeffrey S. Ross (ORCID: https://orcid.org/0000-0001-8494-2596)
- Devashish Desai (ORCID: https://orcid.org/0000-0003-4487-6293)
- David M. Jones
Institutions
- Berkshire Medical Center (US)
- University of Miami (US)
- Duke University (US)
- SUNY Upstate Medical University (US)
- Boston Foundation (US)
- Foundation Medicine (United States)
Publication Details
- Journal
- Journal of Cutaneous Pathology
- Published
- 2024-09-15
- DOI
- https://doi.org/10.1111/cup.14713
- Citations
- 3
- Primary Topic
- Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.85